Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL018
MIFTS: 48

Childhood Medulloblastoma

Categories: Rare diseases, Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Medulloblastoma

About this section

MalaCards integrated aliases for Childhood Medulloblastoma:

Name: Childhood Medulloblastoma 12 53 15
Medulloblastoma, Childhood 53 73
Pediatric Medulloblastoma 12
Medulloblastoma Childhood 55

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3869
MeSH 44 D008527
NCIt 50 C3997
UMLS 73 C0278510
Sources

Summaries for Childhood Medulloblastoma

About this section
MalaCards based summary : Childhood Medulloblastoma, also known as medulloblastoma, childhood, is related to medulloblastoma and askin's tumor, and has symptoms including headache, vomiting and gait ataxia. An important gene associated with Childhood Medulloblastoma is CRNDE (Colorectal Neoplasia Differentially Expressed
Long non-coding RNA CRNDE promotes tumor growth in medulloblastoma
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Apoptosis Pathway and Proteoglycans in cancer. The drugs Cisplatin and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are behavior/neurological and cardiovascular system

Sources

Related Diseases for Childhood Medulloblastoma

About this section

Diseases related to Childhood Medulloblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
# Related Disease Score Top Affiliating Genes
1 medulloblastoma 27.7 DDX3X ERBB3 ERBB4 MYC MYCN NTRK3
2 askin's tumor 10.5 MYC MYCN
3 vulva basal cell carcinoma 10.5 MYC PTCH1
4 bone ewing's sarcoma 10.5 MYC MYCN
5 cerebral primitive neuroectodermal tumor 10.4 MYC MYCN
6 nodular medulloblastoma 10.3 PTCH1 SUFU
7 microform holoprosencephaly 10.3 PTCH1 SUFU
8 medullomyoblastoma 10.2 MYC MYCN
9 cerebellar liponeurocytoma 10.2 PTCH1 SUFU
10 large cell medulloblastoma 10.1 MYC PRDM13
11 adult medulloblastoma 10.0 MYCN PTCH1 SUFU
12 ewing's family of tumors 10.0
13 keratocystic odontogenic tumor 9.9 PTCH1 SUFU
14 brain cancer 9.9 MYCN NTRK3 PTCH1
15 aging 9.8
16 thyroiditis 9.8
17 nervous system cancer 9.7 MYC MYCN PTCH1 SUFU
18 basal cell carcinoma 1 9.7
19 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
20 hepatitis 9.7
21 hypothyroidism 9.7
22 atypical teratoid rhabdoid tumor 9.7
23 basal cell carcinoma 9.7
24 cerebritis 9.7
25 rhabdoid cancer 9.7
26 supratentorial primitive neuroectodermal tumor 9.7
27 ependymoma 9.7
28 radiation induced cancer 9.7
29 infratentorial cancer 9.3 MYC MYCN NTRK3 PTCH1 SUFU
30 adenocarcinoma 9.2 ERBB3 ERBB4 NTRK3

Graphical network of the top 20 diseases related to Childhood Medulloblastoma:



Diseases related to Childhood Medulloblastoma
Sources

Symptoms & Phenotypes for Childhood Medulloblastoma

About this section

UMLS symptoms related to Childhood Medulloblastoma:


headache, vomiting, gait ataxia

MGI Mouse Phenotypes related to Childhood Medulloblastoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 SH3GL1 PRDM13 PTCH1 ERBB3 MYCN ERBB4
2 cardiovascular system MP:0005385 10.1 SUFU PTCH1 ERBB3 MYCN ERBB4 NTRK3
3 mortality/aging MP:0010768 10.06 SH3GL1 SUFU PTCH1 ERBB3 MYCN ERBB4
4 growth/size/body region MP:0005378 10.03 PTCH1 SH3GL1 SUFU ERBB3 MYCN NTRK3
5 nervous system MP:0003631 10.02 SH3GL1 SUFU PRDM13 PTCH1 MYCN ERBB4
6 embryo MP:0005380 10 SUFU PTCH1 ERBB3 MYCN ERBB4 MYC
7 craniofacial MP:0005382 9.88 PTCH1 SUFU MYCN ERBB4 MYC
8 muscle MP:0005369 9.85 PTCH1 ERBB3 MYCN ERBB4 MYC DDX3X
9 normal MP:0002873 9.81 SH3GL1 SUFU PTCH1 ERBB4 NTRK3 MYC
10 no phenotypic analysis MP:0003012 9.65 PTCH1 SUFU MYCN NTRK3 MYC
11 pigmentation MP:0001186 9.26 PTCH1 SUFU ERBB3 MYC
12 respiratory system MP:0005388 9.17 SH3GL1 SUFU PTCH1 MYCN ERBB4 NTRK3
Sources

Drugs & Therapeutics for Childhood Medulloblastoma

About this section

Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
2
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
4
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
9
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
10
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
11
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
12
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
14
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Isotretinoin Approved Phase 3,Phase 1,Not Applicable 4759-48-2 5538 5282379
17
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
18
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
21 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimetabolites Phase 3,Phase 2,Not Applicable
26 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
27 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
30 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
34 Vitamin B Complex Phase 3,Phase 2,Not Applicable
35 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
36 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Liver Extracts Phase 3,Phase 2,Phase 1
38 Antidotes Phase 3,Phase 2,Phase 1
39 Calcium, Dietary Phase 3,Phase 2
40 Micronutrients Phase 3,Phase 2
41 Trace Elements Phase 3,Phase 2
42 Vitamins Phase 3,Not Applicable
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Anti-Infective Agents Phase 3,Phase 2,Phase 1
45 Antioxidants Phase 3,Phase 1,Phase 2
46 Antitubercular Agents Phase 3,Phase 1,Phase 2
47 Chelating Agents Phase 3,Phase 1,Phase 2
48 sodium thiosulfate Phase 3,Phase 1,Phase 2
49 Antiemetics Phase 3,Phase 1
50 Autonomic Agents Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 134)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
2 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
3 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed NCT00085735 Phase 3 Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
4 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
5 Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
6 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
7 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
8 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
9 Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma Recruiting NCT00392327 Phase 3 Vincristine Sulfate;Carboplatin;Cisplatin;Cyclophosphamide;Isotretinoin
10 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
11 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
12 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
13 Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery Unknown status NCT00276666 Phase 2 cisplatin;lomustine;vincristine sulfate
14 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
15 Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma Completed NCT02017964 Phase 2 Vincristine Sulfate;Cyclophosphamide;Methotrexate;Etoposide;Carboplatin
16 Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Completed NCT01239316 Phase 2 Vismodegib
17 Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma Completed NCT00003573 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
18 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
19 Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors Completed NCT00025077 Phase 2 carboplatin;cyclophosphamide;thiotepa
20 Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors Completed NCT00002594 Phase 2 cyclophosphamide;melphalan
21 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
22 Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors Completed NCT00003203 Phase 2 carboplatin;cisplatin;cyclophosphamide;vincristine sulfate
23 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
24 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
25 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
26 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
27 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
28 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2 topotecan hydrochloride
29 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
30 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
31 Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
32 Lobradimil and Carboplatin in Treating Children With Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
33 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2 phenylacetate
34 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
35 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
36 Docetaxel in Treating Children With Recurrent Solid Tumors Completed NCT00002825 Phase 2 docetaxel
37 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
38 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
39 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
40 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
41 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
42 Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Recruiting NCT02684071 Phase 2 Intra thecal methotrexate;topotecan;cyclophosphamide
43 WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Recruiting NCT02095132 Phase 1, Phase 2 Adavosertib;Irinotecan Hydrochloride
44 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
45 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
46 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
47 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting NCT01878617 Phase 2 Cyclophosphamide;Cisplatin;Vincristine;Vismodegib;Pemetrexed;Gemcitabine
48 Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting NCT02624388 Phase 2 Genistein;Placebo
49 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Active, not recruiting NCT01217437 Phase 2 Irinotecan Hydrochloride;Temozolomide
50 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2

Search NIH Clinical Center for Childhood Medulloblastoma

Sources

Genetic Tests for Childhood Medulloblastoma

About this section
Sources

Anatomical Context for Childhood Medulloblastoma

About this section

MalaCards organs/tissues related to Childhood Medulloblastoma:

41
Brain, Bone, Bone Marrow, Testes, Spinal Cord, T Cells, Endothelial
Sources

Publications for Childhood Medulloblastoma

About this section

Articles related to Childhood Medulloblastoma:

(show top 50) (show all 132)
# Title Authors Year
1
Neuropsychological consequences of childhood medulloblastoma and possible interventions: A review. ( 29716738 )
2018
2
Study on Contribution of Biological Interpretable and Computer-Aided Features Towards the Classification of Childhood Medulloblastoma Cells. ( 29974336 )
2018
3
National cancer registry and broad institutional cooperation: turning points in treating childhood medulloblastoma in Iran. ( 29804211 )
2018
4
Intellectual, educational, and situation-based social outcome in adult survivors of childhood medulloblastoma. ( 29336639 )
2018
5
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. ( 28545823 )
2017
6
Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. ( 29189165 )
2017
7
Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia. ( 28717752 )
2017
8
Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. ( 28039368 )
2016
9
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. ( 27040285 )
2016
10
Childhood medulloblastoma. ( 27375228 )
2016
11
Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns. ( 27770281 )
2016
12
The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ( 27785591 )
2016
13
Evolving molecular era of childhood medulloblastoma: time to revisit therapy. ( 26617331 )
2016
14
Evidence of high mortality in long term survivors of childhood medulloblastoma. ( 25557108 )
2015
15
CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma. ( 26290144 )
2015
16
The use of 5-ALA to assist complete removal of residual non-enhancing part of childhood medulloblastoma: a case report. ( 26070965 )
2015
17
Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature. ( 24276042 )
2014
18
The biologic era of childhood medulloblastoma and clues to novel therapies. ( 24754593 )
2014
19
NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. ( 24708907 )
2014
20
Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. ( 25346052 )
2014
21
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. ( 24569911 )
2014
22
Germline Mutations in SUFU Cause Gorlin Syndrome-Associated Childhood Medulloblastoma and Redefine the Risk Associated With PTCH1 Mutations. ( 25403219 )
2014
23
miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. ( 23970061 )
2013
24
A contemporary review of molecular candidates for the development and treatment of childhood medulloblastoma. ( 23292496 )
2013
25
Treatment options for childhood medulloblastoma. ( 24069828 )
2013
26
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. ( 22153558 )
2012
27
Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. ( 22994552 )
2012
28
Identification of suitable endogenous control genes for microRNA expression profiling of childhood medulloblastoma and human neural stem cells. ( 22980291 )
2012
29
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. ( 22139329 )
2012
30
Cerebral white matter integrity and executive function in adult survivors of childhood medulloblastoma. ( 23095827 )
2012
31
An exploratory case-only analysis of gene-hazardous air pollutant interactions and the risk of childhood medulloblastoma. ( 22389292 )
2012
32
Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. ( 22350379 )
2012
33
Low-grade bone lesions in survivors of childhood medulloblastoma/primitive neuroectodermal tumor. ( 22054800 )
2012
34
Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile. ( 22826514 )
2012
35
Chemotherapy dose-intensity and survival for childhood medulloblastoma. ( 22993333 )
2012
36
Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. ( 20931205 )
2011
37
Early traits of metabolic syndrome in pediatric post-cancer survivors: outcomes in adolescents and young adults treated for childhood medulloblastoma. ( 22218450 )
2011
38
Risk-adapted chemotherapy in childhood medulloblastoma. ( 21554052 )
2011
39
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. ( 21931624 )
2011
40
Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. ( 21367970 )
2011
41
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. ( 20845476 )
2011
42
Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. ( 21317922 )
2011
43
Intact language skills and semantic processing speed following the use of fractionated cranial irradiation therapy for the treatment of childhood medulloblastoma: a 4-year follow-up study. ( 21207315 )
2011
44
Expression of Oa8P-methylguanine-DNA methyltransferase in childhood medulloblastoma. ( 20820873 )
2011
45
Recurrence in childhood medulloblastoma. ( 21069427 )
2011
46
Childhood medulloblastoma. ( 21129995 )
2011
47
Progress in sequencing human cancer genomes: advancements in childhood medulloblastoma. ( 21900800 )
2011
48
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. ( 20921458 )
2011
49
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. ( 20940197 )
2010
50
Childhood medulloblastoma: current status of biology and treatment. ( 20297854 )
2010
Sources

Variations for Childhood Medulloblastoma

About this section
Sources

Expression for Childhood Medulloblastoma

About this section
Search GEO for disease gene expression data for Childhood Medulloblastoma.
Sources

Pathways for Childhood Medulloblastoma

About this section

Pathways related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Apoptosis Pathway 72
Show member pathways
 11.97 ERBB3 ERBB4 NTRK3
2
Proteoglycans in cancer 37
11.76 ERBB3 ERBB4 MYC PTCH1
3
AKT Signaling Pathway 67
11.71 ERBB3 ERBB4 MYC NTRK3
4
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.11 ERBB3 ERBB4 MYC NTRK3
5
Alzheimers Disease Pathway 64
10.79 ERBB3 ERBB4 NTRK3
6
Notch Pathway 72
10.02 MYC MYCN
Sources

GO Terms for Childhood Medulloblastoma

About this section

Cellular components related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basal plasma membrane GO:0009925 8.96 ERBB3 ERBB4
2 receptor complex GO:0043235 8.8 ERBB3 ERBB4 NTRK3

Biological processes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.87 ERBB4 MYC MYCN PTCH1
2 positive regulation of cell proliferation GO:0008284 9.83 ERBB4 MYC MYCN NTRK3
3 heart development GO:0007507 9.77 ERBB3 ERBB4 NTRK3
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 ERBB3 ERBB4 NTRK3
5 peptidyl-tyrosine phosphorylation GO:0018108 9.67 ERBB3 ERBB4 NTRK3
6 positive regulation of MAPK cascade GO:0043410 9.65 ERBB3 ERBB4 NTRK3
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.63 ERBB3 ERBB4 NTRK3
8 branching involved in ureteric bud morphogenesis GO:0001658 9.61 MYC PTCH1
9 negative regulation of osteoblast differentiation GO:0045668 9.61 PTCH1 SUFU
10 negative regulation of signal transduction GO:0009968 9.61 ERBB3 ERBB4 NTRK3
11 cellular response to epidermal growth factor stimulus GO:0071364 9.6 ERBB4 MYC
12 ERBB2 signaling pathway GO:0038128 9.58 ERBB3 ERBB4
13 liver regeneration GO:0097421 9.56 MYC PTCH1
14 regulation of cell motility GO:2000145 9.55 ERBB3 ERBB4
15 positive regulation of mesenchymal cell proliferation GO:0002053 9.54 MYC MYCN
16 negative regulation of smoothened signaling pathway GO:0045879 9.51 PTCH1 SUFU
17 negative regulation of ERBB signaling pathway GO:1901185 9.4 ERBB3 ERBB4
18 mammary gland epithelial cell differentiation GO:0060644 9.37 ERBB4 PTCH1
19 negative regulation of apoptotic process GO:0043066 9.35 DDX3X ERBB3 ERBB4 MYC NTRK3
20 positive regulation of kinase activity GO:0033674 9.33 ERBB3 ERBB4 NTRK3
21 negative regulation of astrocyte differentiation GO:0048712 9.32 MYCN NTRK3
22 negative regulation of cell division GO:0051782 9.26 MYC PTCH1
23 positive regulation of gene expression GO:0010628 9.02 DDX3X ERBB3 MYC MYCN NTRK3

Molecular functions related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.5 ERBB3 ERBB4 NTRK3
2 MAP kinase kinase kinase activity GO:0004709 9.33 ERBB3 ERBB4 NTRK3
3 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 ERBB3 ERBB4
4 mitogen-activated protein kinase kinase binding GO:0031434 9.13 ERBB3 ERBB4 NTRK3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 ERBB3 ERBB4 NTRK3
Sources

Sources for Childhood Medulloblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....